rs5882 — CETP I405V

Missense variant that reduces CETP enzyme activity, raising HDL-C and enlarging lipoprotein particles; the Val/Val (GG) genotype is enriched in Ashkenazi Jewish centenarians and associated with slower cognitive decline

See your personal result for CETP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CETP I405V — The Longevity Lipid Variant

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that moves cholesterol esters from HDL to LDL and VLDL, simultaneously transferring triglycerides in the opposite direction. This exchange is a central step in reverse cholesterol transport — the process by which excess cholesterol is harvested from peripheral tissues and returned to the liver for excretion. High CETP activity tends to lower HDL levels and shrink HDL particle size; low CETP activity allows HDL to accumulate as larger, more cholesterol-rich particles.

The I405V variant at rs5882 sits in exon 14 of the CETP gene11 exon 14 of the CETP gene
located on chromosome 16q13, encoding a 476-amino-acid secreted glycoprotein. Unlike the TaqIB variant (rs708272), which is a non-functional intronic marker in linkage with the functional haplotype, I405V is a direct coding change — substituting isoleucine (Ile) for valine (Val) at mature-protein position 405 (precursor position 422). This direct amino acid substitution reduces CETP secretion from hepatocytes and lowers circulating CETP protein levels.

The Mechanism

At the molecular level, the Val allele (G on the plus strand) reduces CETP protein expression. Carriers of the Val allele have measurably lower serum CETP concentrations: in the original Barzilai cohort, VV centenarians showed CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01)22 CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01). Lower CETP activity allows HDL particles to retain their cholesteryl ester cargo longer, producing larger, more buoyant HDL2 particles and elevating total HDL-C. Studies suggest VV carriers tend to have higher HDL-C levels, with the effect more pronounced in women.

The relationship between I405V and cognitive health has a plausible mechanism: HDL particles deliver cholesterol to the brain through the blood–brain barrier, and larger, lipid-rich HDL particles may support neuronal membrane integrity and myelin maintenance. Reduced CETP activity may also lower apolipoprotein B–containing particles in cerebrospinal fluid, decreasing amyloid deposition.

The Evidence

The landmark study was Barzilai et al., JAMA 200333 Barzilai et al., JAMA 2003, which genotyped 213 Ashkenazi Jewish centenarians (mean age 98.2 years), 216 of their offspring, and 258 age-matched controls. Centenarians and their offspring showed 2.9- to 3.6-fold enrichment (in men) and 1.5- to 2.7-fold enrichment (in women) for the VV genotype compared to controls, alongside larger HDL and LDL particle sizes, lower hypertension prevalence, and lower rates of metabolic syndrome.

The longevity-cognition link was formalized in Barzilai et al., Neurology 2006 44 Barzilai et al., Neurology 2006 : among cognitively intact centenarians (MMSE >25), 29% were VV vs only 14% of those with MMSE ≤25 (p=0.02). In a younger cohort (Einstein Aging Study), VV subjects showed a fivefold increase compared to expected frequency. The most quantitatively precise evidence comes from Sanders et al. 201055 Sanders et al. 2010: following 523 older adults for a mean 4.3 years, VV homozygotes showed significantly slower memory decline (p=0.03) and dramatically lower dementia risk (HR 0.28, 95% CI 0.10–0.85, p=0.02) and Alzheimer's disease risk (HR 0.31, 95% CI 0.10–0.95, p=0.04). The large Cache County Study66 Cache County Study, with 4,486 subjects followed over 12 years, found each additional Val allele associated with 0.6-point/year slower cognitive decline (p=0.011).

Importantly, this picture is not universal. Yu et al. 201277 Yu et al. 2012 found the opposite in 1,384 European-ancestry participants: VV genotype was associated with faster cognitive decline and higher AD risk (HR 1.63). A Chinese case-control meta-analysis 88 Chinese case-control meta-analysis across 8 studies found the V allele was protective in Ashkenazi Jews (OR 1.46) but a risk allele in East Asian populations (OR 0.67). The APOE interaction99 APOE interaction may partly explain this: in APOE ε4 carriers, the V allele associates with preserved cortical thickness; in non-carriers, the I allele is protective. The cardiovascular evidence is similarly mixed — the Val allele reliably raises HDL but does not consistently reduce cardiovascular events, mirroring failures of CETP inhibitor drugs in clinical trials.

Practical Actions

For GG (VV) carriers, the primary implication is the established HDL-raising effect: monitor HDL particle size (not just HDL-C) to confirm the phenotypic benefit, and support it through dietary choices known to synergize with endogenous CETP inhibition. Plant sterols (2 g/day) significantly lower triglycerides in GG individuals specifically, with no effect in other genotypes — making this a targeted dietary intervention. Niacin also raises HDL and reduces CETP activity, potentially amplifying the GG genotype's effect.

For AA (II) carriers, HDL-C and HDL particle size are worth monitoring, as higher CETP activity tends to produce smaller, denser HDL particles. Dietary strategies that modulate CETP activity — plant sterols, omega-3 fatty acids, moderate alcohol avoidance — may partially compensate for the higher CETP burden.

Interactions

The most clinically relevant interaction is with APOE genotype. The APOE ε4 allele independently raises Alzheimer's disease risk and alters lipid metabolism. In APOE ε4 carriers, the CETP Val allele appears to protect against medial temporal lobe atrophy; in non-carriers, the Ile allele is paradoxically protective. This complex interaction suggests that CETP I405V genotype should be interpreted alongside APOE status, and the net effect on neurological risk depends substantially on APOE background.

The rs708272 TaqIB variant (in the heart-inflammation category) is in strong linkage disequilibrium with rs5882 in European populations, and these two markers tag the same functional haplotype. Both should not be used simultaneously to predict CETP activity — I405V (rs5882) is the direct functional variant, while TaqIB is a proxy.

Nutrient Interactions

plant sterols altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard CETP Activity Normal

Normal CETP activity and standard HDL particle profile

The Ile/Ile genotype produces full-length CETP protein without the amino acid substitution that reduces secretion. Circulating CETP levels in II individuals average approximately 2.1 μg/mL, compared to ~1.7 μg/mL in VV carriers — a roughly 20% higher CETP burden. This accelerates the reverse transfer of cholesteryl esters from HDL to apoB-containing particles, contributing to smaller HDL particle sizes and lower HDL-C relative to Val carriers.

From a longevity standpoint, the II genotype lacks the centenarian enrichment seen with VV. However, the evidence that this translates into meaningfully worse health outcomes is inconsistent across populations. One study (Yu et al. 2012) found VV carriers had higher Alzheimer's risk, suggesting the relationship is not straightforward and likely depends on APOE genotype and other factors. Standard lipid monitoring and lifestyle optimization remain appropriate.

GG Longevity Val/Val Beneficial

Val/Val genotype — reduced CETP activity, enlarged HDL particles, and centenarian enrichment

The Val/Val genotype reduces CETP secretion from hepatocytes, resulting in approximately 20% lower circulating CETP protein (~1.73 vs ~2.12 μg/mL in the Barzilai centenarian cohort). This reduces the rate of cholesteryl ester transfer from HDL to LDL/VLDL, allowing HDL particles to grow larger and more lipid-rich. The net effect is elevated HDL-C and a shift toward larger, more buoyant HDL2 particles — the subclass most strongly associated with cardiovascular protection.

In the Einstein Aging Study (523 older adults, mean 4.3-year follow-up), VV individuals showed significantly slower memory decline (p=0.03) and HR 0.28 for incident dementia and HR 0.31 for Alzheimer's disease. The Cache County Study (4,486 subjects, 12-year follow-up) found 0.6-point/year faster cognitive preservation per Val allele. The cognitive protection may operate through larger HDL particles supporting cerebral cholesterol homeostasis and reducing amyloid burden.

However, the cognitive finding is contested. One large study (Yu et al., 1,384 European-ancestry subjects) found VV individuals had higher AD risk (HR 1.63) and faster working memory decline. APOE genotype may resolve this discrepancy: in APOE ε4 carriers, the Val allele appears protective; in non-carriers, effects may differ. The longevity association is strongest and most consistently replicated in Ashkenazi Jewish populations and weaker or absent in non-Jewish Europeans.

For diet-gene interaction: VV homozygotes specifically lower triglycerides by −0.46 mmol/L when consuming 2 g/day of plant sterols, while AA and AG carriers show no effect from the same intervention (RCT, n=42, p=0.002).

AG Partial CETP Reduction Intermediate

One Val allele — moderately elevated HDL and partial CETP reduction

The IV heterozygote shows an intermediate phenotype: CETP protein levels sit roughly midway between II and VV individuals. Population studies consistently show a gene-dose effect on HDL-C, with each Val allele contributing a measurable but partial increase. In the Polish elderly cohort, II+IV individuals were grouped as the reference against which VV was compared — suggesting IV may not have a phenotype clearly distinct from II in all studies.

The longevity literature is less consistent for the heterozygous state. The centenarian enrichment studies largely focused on VV homozygosity. For cognitive outcomes, the Cache County Study found a dose-dependent effect (0.6 points/year per Val allele), implying IV carriers have intermediate cognitive protection. The practical implications for IV individuals are modest and mainly involve confirming their lipid phenotype matches the expected elevated HDL pattern.